Clinical immunotherapy in pancreatic cancer

Xiaorong Ye,Yue Yu,Xiaohu Zheng,Hongdi Ma

DOI: https://doi.org/10.1007/s00262-024-03632-6

IF: 6.63

2024-03-03

Cancer Immunology Immunotherapy

Abstract:Pancreatic cancer remains a challenging disease with limited treatment options, resulting in high mortality rates. The predominant approach to managing pancreatic cancer patients continues to be systemic cytotoxic chemotherapy. Despite substantial advancements in immunotherapy strategies for various cancers, their clinical utility in pancreatic cancer has proven less effective and durable. Whether administered as monotherapy, employing immune checkpoint inhibitors, tumor vaccines, chimeric antigen receptors T cells, or in combination with conventional chemoradiotherapy, the clinical outcomes remain underwhelming. Extensive preclinical experiments and clinical trials in the realm of pancreatic cancer have provided valuable insights into the complexities of immunotherapy. Chief among the hurdles are the immunosuppressive tumor microenvironment, limited immunogenicity, and the inherent heterogeneity of pancreatic cancer. In this comprehensive review, we provide an overview and critical analysis of current clinical immunotherapy strategies for pancreatic cancer, emphasizing their endeavors to overcome immunotherapy resistance. Particular focus is placed on strategies aimed at reshaping the immunosuppressive microenvironment and enhancing T cell-mediated tumor cell killing. Ultimately, through deeper elucidation of the underlying pathogenic mechanisms of pancreatic cancer and the refinement of therapeutic approaches, we anticipate breakthroughs that will pave the way for more effective treatments in this challenging disease.

oncology,immunology

What problem does this paper attempt to address?

### What problems does this paper attempt to solve?

This paper aims to comprehensively review and analyze the current clinical immunotherapy strategies for pancreatic cancer, with a focus on exploring how to overcome the problem of immunotherapy resistance. Specifically, the paper focuses on the following aspects:

1. **The current status of pancreatic cancer treatment**:
- Pancreatic cancer is a disease with limited treatment options and an extremely high mortality rate. The main treatment method remains systemic cytotoxic chemotherapy.
- Although immunotherapy has made significant progress in other cancers, its clinical effect in pancreatic cancer is not satisfactory.

2. **Challenges in immunotherapy**:
- The immunosuppressive tumor microenvironment, limited immunogenicity, and the heterogeneity of pancreatic cancer are the main obstacles leading to the poor effect of immunotherapy.
- The paper discusses these challenges in detail and proposes possible solutions.

3. **Immune checkpoint inhibitors**:
- It introduces the mechanism of action of immune checkpoint inhibitors such as PD - 1/PD - L1 and CTLA - 4 and their applications in pancreatic cancer.
- It analyzes the effects of single - drug immune checkpoint inhibitors and combination therapies, including combination with chemotherapy and other drugs.

4. **Combination therapies**:
- It explores combination therapy strategies of immune checkpoint inhibitors with chemotherapy, radiotherapy, vascular endothelial growth factor (VEGF) inhibitors, transforming growth factor β (TGF - β) receptor inhibitors, etc.
- It emphasizes the potential and limitations of these combination therapies in improving patient survival rates and remission rates.

5. **Future research directions**:
- The paper points out that by more in - depth elucidation of the pathogenic mechanisms of pancreatic cancer and optimization of treatment strategies, it is expected to achieve more effective treatment methods in the future.
- It particularly emphasizes the importance of remodeling the immunosuppressive microenvironment and enhancing T - cell - mediated tumor cell killing.

In summary, this paper aims to provide new ideas and directions for the treatment of pancreatic cancer through a comprehensive review and analysis of current clinical immunotherapy strategies, in the hope of finally finding more effective treatment methods.